Press release
Fibromyalgia Pipeline 2025: Exploring Breakthrough Therapies, Emerging Drugs, and Future Market Outlook by DelveInsight
Curious about the latest updates in the Fibromyalgia Pipeline? Click here to explore the therapies and trials making headlines @ Fibromyalgia Pipeline Outlook Report [https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Fibromyalgia Pipeline Report
* In July 2025, UCB Biopharma SRL announced a study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).
* DelveInsight's Fibromyalgia Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Fibromyalgia treatment.
* The leading Fibromyalgia Companies such as UCB Biopharma SRL, Tonix Pharmaceuticals, Inc., Dogwood Therapeutics, Silo Pharma and others.
* Promising Fibromyalgia Therapies such as Paroxetine CR, Lacosamide, Milnacipran, Rotigotine, Duloxetine, Rozanolixizumab, ONO-1110 and others.
Want to know which companies are leading innovation in Fibromyalgia? Dive into the full pipeline insights @ Fibromyalgia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Fibromyalgia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Fibromyalgia Pipeline Report also highlights the unmet needs with respect to the Fibromyalgia.
Fibromyalgia Overview
Fibromyalgia Syndrome (FMS) is a chronic condition characterized by widespread musculoskeletal pain, often accompanied by fatigue, sleep disturbances, cognitive dysfunction (fibro fog), and mood disorders such as anxiety and depression. Although the exact cause remains unclear, FMS is thought to result from a combination of genetic, neurobiological, and environmental factors that lead to alterations in pain processing and central sensitization, where the nervous system becomes hypersensitive to pain signals. Affecting approximately 6% to 15% of the population, with a notably higher prevalence in women, fibromyalgia significantly impacts daily life, making routine activities challenging and often leading to impaired physical, emotional, and social functioning.
Fibromyalgia Emerging Drugs
* TNX-102 SL: Tonix Pharmaceuticals, Inc.
TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique patented formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. TNX-102 SL is a centrally acting analgesic that helps in relieving pain by improving sleep. As a multifunctional agent with potent binding and antagonist activities at the serotonin2A, 1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors, TNX-102 SL is in clinical development and has active IND's as a daily bedtime treatment for fibromyalgia. Currently, the drug is in Preregistration stage of its clinical trial for the treatment of Fibromyalgia.
* Rozanolixizumab: UCB Biopharma SRL
Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Fibromyalgia.
* IMC-1: Dogwood Therapeutics
IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1, combines 2 specific mechanisms of action purposely designed to inhibit HSV-1 activation and replication, thereby keeping HSV-1 in a latent (dormant) state or down-regulating HSV-1 from a lytic (active) state back to latency. The famciclovir component of IMC-1 inhibits viral DNA replication and thus inhibits upregulation of the HSV-1 virus. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (COX-2) and to a lesser degree COX-1, enzymes used by HSV-1 to amplify or accelerate its own replication. Currently, the drug is in the Phase II stage of development to treat Fibromyalgia.
If you're tracking ongoing Fibromyalgia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Fibromyalgia Treatment Drugs [https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Fibromyalgia Companies
UCB Biopharma SRL, Tonix Pharmaceuticals, Inc., Dogwood Therapeutics, Silo Pharma and others.
The Fibromyalgia Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Fibromyalgia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fibromyalgia Treatment.
* Fibromyalgia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Fibromyalgia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fibromyalgia market.
Fibromyalgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Fibromyalgia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Fibromyalgia Pipeline Report covers it all - check it out now @ Fibromyalgia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Fibromyalgia Pipeline Report
* Coverage- Global
* Fibromyalgia Companies- UCB Biopharma SRL, Tonix Pharmaceuticals, Inc., Dogwood Therapeutics, Silo Pharma and others.
* Fibromyalgia Therapies- Paroxetine CR, Lacosamide, Milnacipran, Rotigotine, Duloxetine, Rozanolixizumab, ONO-1110 and others.
* Fibromyalgia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Fibromyalgia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Fibromyalgia Treatment landscape in this detailed analysis @ Fibromyalgia Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Fibromyalgia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Fibromyalgia- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* TNX-102 SL: Tonix Pharmaceuticals, Inc.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Rozanolixizumab: UCB Biopharma SRL
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Fibromyalgia- Unmet Needs
* Fibromyalgia- Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fibromyalgia-pipeline-2025-exploring-breakthrough-therapies-emerging-drugs-and-future-market-outlook-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/fibromyalgia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fibromyalgia Pipeline 2025: Exploring Breakthrough Therapies, Emerging Drugs, and Future Market Outlook by DelveInsight here
News-ID: 4187176 • Views: …
More Releases from ABNewswire
Colorado's Psychedelic Renaissance: The Rise of Retreat Centers and What to Watc …
In recent years, Colorado has quietly become a hotspot for the psychedelic wellness movement. What once might have seemed fringe or experimental is now grounding itself in legal frameworks, therapeutic intent, and entrepreneurial energy. Among the most compelling signals of this shift is the growing number of psilocybin retreat centers setting up shop across the state.
From Proposition 122 to a Landscape of Retreats
After Colorado voters approved Proposition 122 [https://leg.colorado.gov/sites/default/files/initiative%2520referendum_proposition%20122%20final%20lc%20packet.pdf] (the…
Avalon Tree Services Highlights the Benefits of Fall Tree Trimming for Atlanta H …
Lilburn, GA - October 8, 2025 - As autumn settles over Greater Atlanta, Avalon Tree Services is reminding homeowners that fall is one of the best times of year for professional tree trimming. With the summer growth season ending and trees beginning to enter dormancy, fall trimming offers significant advantages for tree health, property safety, and long-term landscape maintenance.
"Many people think tree trimming is only for the spring, but fall…
QuoteIQ Transforms Carpet Cleaning Industry with AI-Powered CRM That Helps Small …
Platform's InstaQuote, InstaSchedule, and Route Optimization Features Drive 40% Revenue Growth for Independent Carpet Cleaners While Reducing Administrative Work by 35
QuoteIQ, the fastest-growing business management platform for home service professionals, today announced significant traction in the carpet cleaning sector as independent businesses leverage the company's all-in-one CRM to level the playing field against large franchise operations.
The platform addresses the critical competitive disadvantage small carpet cleaning businesses face when competing with…
Brightway Insurance - Ponte Vedra Beach Named Insurance Journal's 2025 Best Agen …
Ponte Vedra Beach, FL - October 8, 2025 - Brightway Insurance [https://www.brightway.com/agencies/fl/ponte-vedra-south/0008] Ponte Vedra Beach has been named Insurance Journal's 2025 Best Agency to Work For - Southeast, Gold Award Winner. The honor recognizes independent insurance agencies across the U.S. that excel in workplace culture, employee satisfaction, and client care-based entirely on anonymous employee feedback.
Led by Agency Owners Billy Wagner and Chris Huebener, the 17-person Ponte Vedra Beach team credits…
More Releases for Fibromyalgia
Government Initiatives On Musculoskeletal Health Propel Growth In The Fibromyalg …
The Fibromyalgia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Fibromyalgia Treatment Market?
The market for the treatment of fibromyalgia has been expanding consistently in past years. At a compound annual growth rate (CAGR) of 3.9%, it is…
SN Clinic's Effective Treatment of Fibromyalgia Symptoms
Image: https://www.globalnewslines.com/uploads/2025/02/1740408683.jpg
SN Clinic Logo
Fibromyalgia can be a debilitating condition, but SN Clinic offers hope through innovative treatments like MLS Laser Therapy and complementary massage therapies. By addressing chronic pain through a holistic approach, patients can experience significant relief and an improved quality of life.
What is Fibromyalgia and What Does Current Data Say?
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Affecting…
Prominent Fibromyalgia Treatment Market Trend for 2025: Market Leaders Focus On …
What Are the Projected Growth and Market Size Trends for the Fibromyalgia Treatment Market?
The Fibromyalgia Treatment market is expected to grow from $2.79 billion in 2024 to $2.9 billion in 2025, at a CAGR of 3.9%. This growth is attributed to the increasing prevalence of fibromyalgia, greater awareness about the condition, government initiatives, and rising disposable incomes.
The fibromyalgia treatment market is projected to see steady growth, reaching $3.45 billion by…
Advancements in Fibromyalgia Treatments Driving Market Expansion
The fibromyalgia treatment market is experiencing a steady upward trajectory, with significant growth expected over the next decade. Estimated at USD 2.77 billion in 2023, the market is projected to reach approximately USD 4.13 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032. This expansion is driven by several key factors, including advances in treatment options, increasing demand for effective therapies, and…
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues.
Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.
To know more about Fibromyalgia - Drug Pipeline, visit - https://www.globalinsightservices.com/reports/fibromyalgia-drug-pipeline-landscape-2022/
Fibromyalgia…
Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required…
